William Nish, MD
Allergy & Immunology · Gainesville, GANPI 1821097643
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 363 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,738 and has fallen 74.7% since, to $441 in 2025.
Across 363 payments — averaging $22.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Sanofi$1K
- GSK$812
- Regeneron Healthcare Solutions, Inc.$596
- Amgen$548
- Takeda Pharmaceuticals U.S.A., Inc.$436
- plus $3K from 25 others
What the payments were for
- Food & beverage$7,77597%
- Education$2433%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 67 | $1,441 |
| Sanofi | 37 | $1,088 |
| GSK | 50 | $812 |
| Regeneron Healthcare Solutions, Inc. | 25 | $596 |
| Amgen | 22 | $548 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $436 |
| Teva Pharmaceuticals USA, Inc. | 25 | $405 |
| Boehringer Ingelheim | 15 | $312 |
| Pfizer | 14 | $278 |
| Grifols USA, LLC | 12 | $265 |
| Biocryst US Sales Co., LLC | 11 | $245 |
| Novartis | 11 | $208 |
| Optinose US, Inc. | 11 | $204 |
| Sanofi-aventis U.S. LLC | 2 | $189 |
| Kaleo, Inc. | 8 | $135 |
| AbbVie | 6 | $133 |
| Covis Pharma GmbH | 6 | $123 |
| Aimmune Therapeutics, Inc. | 3 | $96 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $87 |
| Octapharma USA, Inc. | 1 | $77 |
| Merck | 3 | $66 |
| Pharming Healthcare, Inc. | 2 | $47 |
| Alk-abello, Inc | 2 | $44 |
| Mylan Specialty L.p. | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $36 |
| ADMA Biomanufacturing LLC | 1 | $26 |
| Incyte Corporation | 1 | $25 |
| Blueprint Medicines Corporation | 1 | $19 |
| Phadia US Inc. | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| Circassia Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,018 in reported general payments places this provider in the 65th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 245 | $184,117 |
| Dupixent PenDupilumab | 39 | $153,557 |
| Breo ElliptaFluticasone/Vilanterol | 95 | $40,933 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $17,313 |
| Spiriva RespimatTiotropium Bromide | 23 | $12,958 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 101 | $11,442 |
| Advair HfaFluticasone Propion/Salmeterol | 30 | $9,864 |
| Incruse ElliptaUmeclidinium Bromide | 26 | $8,747 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $8,593 |
| Arnuity ElliptaFluticasone Furoate | 40 | $8,561 |
| Wixela InhubFluticasone Propion/Salmeterol | 86 | $7,225 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,361 |
| Epinephrine | 32 | $4,404 |
| Zafirlukast | 38 | $3,783 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 123 | $3,711 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta, Anoro Ellipta | $812 | $248,719420 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,441 | $25,90639 claims |
| Boehringer IngelheimSpiriva Respimat | $312 | $12,95823 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $405 | $3,34512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Gainesville
- Ronald BeebeGainesville$56K
- Kimberley ShanksGainesville$11K
- Amy BoydGainesville$8K
- Faria KhanGainesville$7K
- Michael MaloneyGainesville$7K
- Michael BlaissRoswell$1.1M
- Deborah BirxAtlanta$470K
- Tracy BridgesAlbany$364K
- Jack EadesMacon$237K
- Stanley FinemanMarietta$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.